+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07235007

Study of Repeated Endobiliary Radiofrequency Ablation with Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma International Randomized Controlled Trial Evaluating Survival Benefits

Led by Aichi Medical University · Updated on 2026-01-13

120

Participants Needed

8

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying patients with unresectable extrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be surgically removed. The trial evaluates whether repeated endobiliary radiofrequency ablation EB-RFA combined with first-line systemic therapy using durvalumab, gemcitabine, and cisplatin improves overall survival compared to standard plastic stenting alone. This international, open-label, randomized controlled trial addresses the limited survival benefits of current treatments and explores local tumor control through EB-RFA. Participants are randomly assigned to one of two groups one group receives EB-RFA followed by placement of a plastic biliary stent during an initial endoscopy, with a second endoscopy at three months to repeat EB-RFA and stent exchange additional EB-RFA sessions every two months may occur if needed. The other group receives standard plastic stenting without EB-RFA, with scheduled stent exchanges at three months and thereafter as needed. All participants undergo systemic therapy with durvalumab, gemcitabine, and cisplatin throughout the study. During the study, participants undergo scheduled endoscopic procedures and systemic therapy, with researchers monitoring overall survival up to 36 months after enrollment. Secondary measures include time to recurrent biliary obstruction, progression-free survival, adverse events, and success rates of the procedures. The study includes safety monitoring and assessment of repeated biliary interventions and their impact on participants health and treatment outcomes.

CONDITIONS

Brief Title

Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma

Research Team

T

Tadahisa Inoue

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here